Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:


Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Belimumab

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Belimumab: Sponsors, patents, clinical trial progress

Belimumab is an investigational drug.

There have been 45 clinical trials for Belimumab. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2013.

The most common disease conditions in clinical trials are Lupus Erythematosus, Systemic, Glomerulonephritis, Membranous, and Syndrome. The leading clinical trial sponsors are GlaxoSmithKline, Human Genome Sciences Inc., and Human Genome Sciences Inc., a GSK Company.

There are forty US patents protecting this investigational drug and eight hundred and seventy-one international patents.

Recent Clinical Trials for Belimumab
Belimumab With Rituximab for Primary Membranous NephropathyImmune Tolerance Network (ITN)Phase 2
Belimumab With Rituximab for Primary Membranous NephropathyNational Institute of Allergy and Infectious Diseases (NIAID)Phase 2
Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic SclerosisGlaxoSmithKlinePhase 2

See all Belimumab clinical trials

Clinical Trial Summary for Belimumab

Top disease conditions for Belimumab
Top clinical trial sponsors for Belimumab

See all Belimumab clinical trials

US Patents for Belimumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Belimumab   Start Trial Compositions and methods for treating or preventing lupus The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)   Start Trial
Belimumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Belimumab   Start Trial Methods for diagnosing systemic lupus erythematosus Exagen Diagnostics, Inc. (Vista, CA)   Start Trial
Belimumab   Start Trial Constructs having a SIRP-.alpha. domain or variant thereof ALX ONCOLOGY INC. (Burlingame, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Belimumab

Drugname Country Document Number Estimated Expiration Related US Patent
Belimumab Australia 2010364324 2030-11-24   Start Trial
Belimumab Canada 2818712 2030-11-24   Start Trial
Belimumab Japan 2014505020 2030-11-24   Start Trial
Belimumab Japan 5850943 2030-11-24   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.